5α-Reductase inhibitor treatment of prostatic diseases: Background and practical implications

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 2, 2009, Pages 130-136

  Dorsam J ^a   Altwein, J ^b  

^a St Theresien Krankenhaus   (Germany)

^b Chirurgische Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; BICALUTAMIDE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; ANTINEOPLASTIC AGENT; AZASTEROID; ENZYME INHIBITOR;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BREAST TENDERNESS; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RECURRENT CANCER; RISK REDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; DRUG ANTAGONISM; MALE; PROSTATE TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS; AZASTEROIDS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 67349119830     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.56     Document Type: Article

References (63)

1. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell N, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: Results of 4-year studies. BJU Int 2005; 96: 572-577.
2. Russel DW, Wilson JD. Steroid 5α-reductase: Two genes, two enzymes. Annu Rev Biochem 1994; 63: 25-61.
3. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379-385.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics 2006. Ca Cancer J Clin 2006; 56: 106-130.
5. Iehle C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gérard H, Chopin D et al. Differences in steroid 5α-reductase isoenzyme expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68: 189-195.
6. Andriole G, Bruchovsky N, Chung LWK, Matsumoto AM, Rittmaster R, Roehrborn C et al. Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399-1403.
7. Le H, Arnold JT, McFann KK, Blackmann MR. DHT and testosterone but not DHEA or E2 differentially modulate IGF-I, IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab 2006; 290: E952-E960.
8. Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW et al. 5α-Reduction type 1 immunostaining is enhanced in some prostate cancers compared with BPH epithelium. J Urol 2003; 170: 2019-2025.
9. Thomas LH, Lazier CB, Gupta R, Norman RW, Thompson IM, Troyer DA et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostatae cancer. Prostate 2004; 58: 1-9.
10. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5α-reductase 2 in human prostate cancer: Implication for finasteride therapy of prostate carcinoma. Prostate 2003; 57 134-139.
11. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD. Familial incomplete male pseudohermaphroditism type 2. Decreased DHT formation in pseudovaginal, perineoscrotal hypospadias. N Engl J Med 1974; 291: 944-949.
12. Steers WD. 5α-Reductase activity in the prostate. Urology 2001; 58 (Suppl 1): 17-24.
13. Evans HC, Goa KL. Dutasteride. Drugs Aging 2003; 20: 905-916.
14. Frye SV. Discovery and clinical development of dutasteride, a potent dual 5α-reductase inhibitor. Curr Top Med Chem 2006; 6: 405-421.
15. Steiner JF. Clinical pharmacokinetics and pharacodynamics of finasteride. Clin Pharmacokinet 1996; 30: 16-27.
16. Clark RV, Hermann DJ, Cunnungham GR, Wilson TH, Morril BB, Hobbs S. Marked suppression of DHT in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-2184.
17. Marks LS, Roehrborn CG, Rittmaster RS. Duration of DHT suppression following discontinuation of dutasteride: Implication for missed doses. J Urol 2004; 171: 242-243.
18. Andriole GL, Guess HA, Epstein JI, Wise H, Kadman D, Crawford ED et al. Treatment with finasteride preserves usefulness of PSA in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998; 52: 195-202.
19. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum PSA for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasteride. J Urol 2006; 175: 1657-1662.
20. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TMJ, Roehrborn CG. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 45: 488-495.
21. Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol 2006; 176: 1299-1306.
22. Roehrborn CG, Boyle P, Gould AI, Waldstreicher J. Serum PSA as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-589.
23. Roehrborn CG. The potential of serum PSA as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int 2004; 93 (Suppl 1): 21-26.
24. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH et al. Serum PSA is a strong predictor of future prostate growth in men with prostatic hyperplasia. Proscar long-term efficacy and safety study. J Urol 2000; 163: 13-20.
25. Roehrborn CG, Boyle P, Nickel JC. PSA is a significant predictor of objective parameters in men at risk for BPH progression. J Urol 2003; 169: A1362.
26. McConnell JD, Brushkewitz R, Walsh PC, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 1998; 338: 557-563.
27. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63: 709-715.
28. Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmater RS. Relationship among serum testosterone, sexual function and response to treatment in men receiving dutasteride for BPH. J Clin Endocrinol Metab 2006; 91: 1323-1328.
29. Slawin KM, Kattan MW, Roehrborn CG, Wilson T. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with BPH. Urology 2006; 67 84-88.
30. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004; 6 (Suppl 9): S31-S39.
31. Hagerty JA, Ginsberg PC, Metro MJ, Harkaway RC. A prospective, comparative study of the onset of symptomatic benefit of dutasteride versus finasteride in men with BPH in clinical practice. J Urol 2004; 171: 356-359.
32. McConnell JD, Roehrborn CG, Bautista OM, , Andriole Jr GL, Dixon CM, Kusek JW et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med 2003; 349: 2387-2398.
33. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR et al. Combination therapy with doxazosin and finasteride for BPH in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006; 175: 217-224.
34. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. SMART-1: α-blocker therapy can be withdrawn in the majority of men following initial combination therapy with dual 5α-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-466.
35. Speakman M, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F et al. Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/BPH: A combined analysis of external evidence and clinical expertise. Prostate Cancer Prostatic Dis 2005; 8: 369-375.
36. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ et al. Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 2006; 12: 3661-3697.
37. Thompson IM, Goodman J, Tangen CM, Lucia MS, Miller GJ, Ford LG et al The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
38. Klein E. Can prostate cancer be prevented? Nature Clin Pract Urol 2005; 2: 24-31.
39. Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G et al. Associations of serum testosterone with microvessel densitiy, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312-1315.
40. Algaba F, Epstein JI, Aldape HC, Farrow GM, Lopez-Beltran A, Maksem J et al. Assessment of prostate carcinoma in core needle biopsy - definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996; 78: 376-381.
41. Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montirone R. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004; 2: 228-235.
42. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan Jr ED. The influence of prostate size on cancer detection. Urology 1995; 46: 831-836.
43. Akduman B, Crawford ED. Treatment of localized prostate cancer. Rev Urol 2006; 8 (Suppl 2): S15-S21.
44. Marberger M, Adolfsson J, Borkowski A, Fitzpatrick J, Kirk D, Prezioso D et al. The clinical implications of the prostate cancer prevention trial. BJU Int 2003; 92: 667-671.
45. Redman MV, Tangen CM, Goodman PJ, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: A bias adjusted modelling approach. Cancer Prev Res 2008; doi: 10.1158/ 1940-6207.CAPR-08-0092.
46. Lamb JC, Levy MA, Johnson RK, Isaacs JT. Response of rat and human prostatic cancers to the novel 5a-reductase inhibitor, SK&F 105657. Prostate 1992; 21: 15-34.
47. Negri-Cesi P, Colciago A, Poletti A, Motta M. 5α-reductase isoenzymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU 145 and PC 3. Prostate 1999; 41: 224-232.
48. Gregory CW, Hohnson RT, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-2898.
49. Zhu YS, Cai LQ, You X, Cordero JJ, Huang J, Imperato-McGinley J. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J Androl 2003; 24: 681-687.
50. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006; 12: 4072-4079.
51. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the 5α-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004; 58 130-144.
52. Bonkhoff H, Stein U, Aumüller G, Remberger K. Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996; 29: 261-267.
53. Festuccia C, Angeluzzi A, Gravina GL, Muzi P, Vicentini C, Bologna M. Effects of 5a-reductase inhibitors on androgen-dependent human prostatic carcinoma cells. J Cancer Res Clin Oncol 2005; 131: 243-254.
54. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10: 7121-7126.
55. Mohler JL, Gregory CW, Ford III OH, Kim D, Weaver CM, Petrusz P et al The androgen axis in recurrent cancer. Clin Cancer Res 2004; 10: 440-448.
56. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11: 4653-4657.
57. Page ST, Lin DW, Mostaghel EA, Dess DL, True LD, Amory JK et al. Persistent intraprostatic androgen concentrations after medical castration in healthy med. J Clin Endocrinol Metab 2006; 91: 3050-3058.
58. Titus MA, Gregory CW, Ford III OH, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005; 11: 4365-4371.
59. Fleshner NE, Trachtenberg J. Combination of finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects. J Urol 1995; 154: 1642-1646.
60. Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003; 62: 872-876.
61. Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R et al. The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer - results from a 4-month pre-radical prostatectomy study. Prostate 2006; 66: 1674-1685.
62. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B. Efficacy of neoadjuvant bicalutamide and dutasteride as cytoreductive regimen before prostate brachytherapy. Urology 2006; 68: 116-120.
63. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja S et al. Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007; 28: 763-769.